Genscript Biotech

1548.HKPre-clinical

Founded in 2002 and publicly listed on the Hong Kong Stock Exchange, Genscript Biotech has evolved from a pioneering gene synthesis service provider into a fully integrated global biotechnology platform. The company operates through three core segments: Life Science Services and Products, Biologics Contract Development and Manufacturing (CDMO), and its own innovative cell therapy pipeline. Its strategic focus includes leveraging its strong R&D foundation to advance proprietary cell therapies while expanding its global CDMO footprint to capture the booming biologics and cell/gene therapy market.

Market Cap

$3.1B

Employees

6,000+

Focus

Biotech

1548.HK · Stock Price

USD 11.1018.70 (-62.75%)

Historical price data

AI Company Overview

Technology Platform

A fully integrated suite of platforms including patented high-throughput gene synthesis, antibody discovery and engineering, end-to-end biologics and cell/gene therapy CDMO services, and a proprietary cell therapy R&D engine.

Funding History

Total raised: $245M

IPO$240MUndisclosedJun 24, 2015

Series A$5MUndisclosedJun 15, 2006

Opportunities

Massive growth opportunity in the global cell and gene therapy CDMO market, particularly for viral vector manufacturing.

Significant upside potential if its internal solid tumor CAR-T programs demonstrate clinical efficacy, unlocking access to much larger patient populations than current hematological indications.

Risk Factors

High clinical failure risk for novel solid tumor CAR-T candidates.

Intense competition and potential pricing pressure in the commercial CAR-T market.

Geopolitical tensions between the US and China could disrupt operations, supply chains, and market access.

Competitive Landscape

Faces competition across all segments: vs. Thermo Fisher/Twist in life science tools, vs. Lonza/WuXi in CDMO, and vs. Gilead/BMS in CAR-T therapeutics. Its differentiation lies in its fully integrated 'platform' model, combining high-margin services with proprietary drug development, creating a unique financial and strategic profile.

Publications